Literature DB >> 15876918

Epidemiology of pertussis.

Tina Tan1, Evelinda Trindade, Danuta Skowronski.   

Abstract

The World Health Organization recommended that a pertussis incidence of <1 case per 100,000 population be achieved in Europe by 2000. Available data indicate that this goal has generally not been achieved, and the incidence is actually rising in some countries. Understanding the reasons for this increased incidence may lead to better global control of pertussis. In the majority of countries where pertussis is a notifiable disease, a case-based national surveillance system is in place. However, different case definitions, methods of diagnosis and reporting and surveillance systems make direct intercountry comparisons difficult, and pertussis is not a statutory notifiable disease in every country. Nevertheless the general consensus is that reported incidences are probably considerably lower than the actual incidence of pertussis; underreporting is common. Prolonged cough may be the only clinical feature in adolescents or adults, who may present for diagnosis late (precluding laboratory confirmation) or not at all. When they do present, their condition is often misdiagnosed because, in part, clinicians continue to perceive pertussis as a childhood disease. Despite underreporting, an increased incidence of infant, adolescent and adult pertussis has been observed worldwide since the introduction of widespread vaccination. This is of concern because adolescents and adults have been identified as a source of transmission of pertussis to very young infants who are unimmunized or partially immunized and thus more vulnerable to disease-related complications and higher mortality. In recent years, acellular pertussis vaccines have been incorporated into the immunization schedules of many developed countries, gradually replacing whole cell vaccines. Dosing schedules vary between countries, although primary immunization with 3 doses of the pertussis vaccine within the first 6 months of life exists in most countries. Only Australia, Austria, Canada, France and Germany have incorporated an adolescent booster dose into their current immunization schedules, in recognition of the rising incidence of pertussis in adolescents and adults. Despite high coverage rates for primary immunization in infants and children, pertussis continues to be a global concern, with increased incidence widely noted. This global epidemiologic summary highlights differences worldwide in pertussis reporting, incidence and approaches to prevention. It underscores a general shift in the age distribution of pertussis toward older groups. Understanding the link between these observations may lead to better informed global control strategies, especially those pertaining to immunization schedules and use of pertussis vaccine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15876918     DOI: 10.1097/01.inf.0000160708.43944.99

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  61 in total

1.  Antibody response from whole-cell pertussis vaccine immunized Brazilian children against different strains of Bordetella pertussis.

Authors:  Alexandre Pereira; Aparecida S Pietro Pereira; Célio Lopes Silva; Gutemberg de Melo Rocha; Ivo Lebrun; Osvaldo A Sant'Anna; Denise V Tambourgi
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

Review 2.  Reduced-antigen, combined diphtheria-tetanus-acellular pertussis vaccine, adsorbed (Boostrix) US formulation): use as a single-dose booster immunization in adolescents aged 10-18 years.

Authors:  James E Frampton; Susan J Keam
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

3.  Enhanced surveillance for adverse events following immunization: Two years of dTap catch-up among high school students in Yukon, Canada (2004, 2005).

Authors:  Samara T David; Mhsc Colleen Hemsley; Paula E Pasquali; Bryce Larke; Jane A Buxton; Lee Y Lior
Journal:  Can J Public Health       Date:  2006 Nov-Dec

4.  Recent findings on pertussis epidemiology in Turkey.

Authors:  D Dilli; I Bostanci; Y Dallar; T Buzgan; H Irmak; M A Torunoğlu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-09       Impact factor: 3.267

5.  Epidemiological characteristics of pertussis in Estonia, Lithuania, Romania, the Czech Republic, Poland and Turkey-1945 to 2005.

Authors:  Irja Lutsar; Ioana Anca; Mustafa Bakir; Vytautas Usonis; Roman Prymula; Nuran Salman; Pawel Grezesiowski; Michael Greenberg
Journal:  Eur J Pediatr       Date:  2008-07-05       Impact factor: 3.183

6.  Deciphering the impacts of vaccination and immunity on pertussis epidemiology in Thailand.

Authors:  Julie C Blackwood; Derek A T Cummings; Hélène Broutin; Sopon Iamsirithaworn; Pejman Rohani
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-20       Impact factor: 11.205

Review 7.  Protective Effect of Contemporary Pertussis Vaccines: A Systematic Review and Meta-analysis.

Authors:  T Roice Fulton; Varun K Phadke; Walter A Orenstein; Alan R Hinman; Wayne D Johnson; Saad B Omer
Journal:  Clin Infect Dis       Date:  2016-02-07       Impact factor: 9.079

8.  Natural immune boosting in pertussis dynamics and the potential for long-term vaccine failure.

Authors:  Jennie S Lavine; Aaron A King; Ottar N Bjørnstad
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-21       Impact factor: 11.205

9.  Update on available vaccines in India: report of the APPA VU 2010: I.

Authors:  Sunil Karande
Journal:  Indian J Pediatr       Date:  2011-03-05       Impact factor: 1.967

10.  The distribution over time of costs and social net benefits for pertussis immunization programs.

Authors:  Dorota Zdanowska Girard
Journal:  Int J Health Care Finance Econ       Date:  2009-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.